Jul 30, 2026 | New
GAITHERSBURG, Md.–(BUSINESS WIRE)–miRecule, Inc., a biotechnology company developing next-generation RNA therapeutics for rare genetic diseases, today announced a strategic research collaboration with Rio Biofarma Brasil Ltda. (RBBL), part of EMS S.A.,...
Mar 18, 2026 | New
GAITHERSBURG, Md.–(BUSINESS WIRE)–Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration focuses on delivering...
Oct 28, 2025 | New
GAITHERSBURG, MD – October 28, 2025 – Anthony Saleh (CEO) will present miRecule at the upcoming MACC Conference in Philadelphia on Thursday, October 30 at 12:10 PM, as part of the Healthcare-Biotech track companies presenting at the conference.
Oct 10, 2025 | New
GAITHERSBURG, MD – October 9, 2025 – miRecule, Inc. today announced that Dr. Hunter Wallace will present data from its collaboration with Sanofi at the 21st Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Budapest, Hungary. The presentation will...
Oct 9, 2024 | New
GAITHERSBURG, MD – October 1, 2024 – miRecule, a biopharmaceutical company focused on developing antibody RNA conjugate-based therapeutics for rare genetic diseases and other conditions, today announced the issuance of U.S. Patent No. 12,104,157, titled...
